Drug Trial Radar · NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 4, 2025
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jan 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Conditions
- Hormone-receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Breast Cancer
Interventions
BGB-21447Drug
Administered orally.
FulvestrantDrug
Administered via intramuscular injection.
BGB-43395Drug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
- Part 1: Recommended Dose for Expansion (RDFE) of BGB-21447 in combination with fulvestrant and in combination with fulvestrant and BGB-43395Time frame: From first dose of the study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 6 to 9 months
- Part 2: Objective Response Rate (ORR)Time frame: Approximately 12 months
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Md Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia · Terminated
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Western Health Sunshine Hospital
St Albans, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Fudan University Shanghai Cancer Centerpudong
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.